Skip to main content

Table 1 Clinical and epidemiological characteristics of all HIV/HCV coinfected patients stratified by PPARγ2 genotype

From: PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study

  

PPARγ2polymorphism

 

All patients (n = 257)

CC (n = 223)

CG/GG (n = 34)

p-value

Gender (male)

191 (74.3%)

165 (74.0%)

26 (76.5%)

0.758

Age (years)

40.9 (37.9; 44.7)

41.0 (37.9; 44.7)

40.1 (36.0; 44.7)

0.675

BMI (kg/m2)

22.5 (20.9; 24.7)

22.5 (20.9; 24.7)

22.6 (20.7; 24.3)

0.875

BMI ≥25 kg/m2

60 (23.4%)

54 (23.9%)

7 (20.6%)

0.674

HIV acquired by IVDU

219 (85_.2%)

191 (85.7%)

28 (82.4%)

0.785

Years since HCV infection

21.3 (16.6; 24.4)

21.6 (16.7; 24.6)

18.5 (16.1; 23.3)

0.149

Prior AIDS

74 (28.8%)

64 (28.7%)

10 (29.4%)

0.973

cART

215 (83.7%)

186 (83.4%)

29 (85.3%)

0.831

Time on cART (years)

4.8 (2.9; 7.8)

4.7 (2.7; 7.7)

4.9 (3.3; 8.7)

0.490

Current cART protocols

    

Any NRTIs + any PI

62 (24.1%)

51 (22.9%)

11 (32.4%)

0.229

Any NRTIs + PI + NNRTI

3 (1.2%)

2 (0.9%)

1 (2.9%)

0.301

Any NRTIs + any NNRTI

130 (50.6%)

114 (51.1%)

16 (47.1%)

0.659

Only NRTIs

20 (7.8%)

19 (8.5%)

1 (2.9%)

0.258

Specific antiretroviral drugs

    

Zidovudine

71 (7.6%)

63 (28.8%)

8 (23.5%)

0.566

Stavudine

66 (25.7%)

55 (25.4%)

11 (32.4%)

0.339

Didanosine

41 (16.0%)

35 (15.7%)

6 (17.6%)

0.772

Tenofovir

70 (27.2%)

59 (26.5%)

11 (32.4%)

0.472

Abacavir

43 (16.7%)

41 (18.4%)

2 (5.9%)

0.069

Efavirenz

76 (29.6%)

72 (32.3%)

4 (11.8%)

0.015

Ritonavir

47 (18.3%)

38 (17.0%)

9 (26.5%)

0.185

HIV markers

    

Nadir CD4+ T-cells (cells/μL)

208 (93; 314.5)

195 (92.5; 306)

257 (145; 364)

0.176

CD4+ T cells/μL

467 (341.7; 670.7)

467 (340; 660)

471 (368; 690)

0.678

HIV-RNA <50 copies/mL

76.6% (196/256)

77.5% (172/222)

70.6% (24/34)

0.377

HCV markers

    

HCV-genotype 1/4

72.7% (181/249)

72.1% (155/215)

76.5% (26/34)

0.594

HCV-RNA ≥500,000 UI/ml

75.6% (186/246)

74.5% (158/212)

82.4% (28/34)

0.324

Significant fibrosis (F ≥ 2)

47.8% (99/207)

46.7% (85/182)

56.0% (14/25)

0.383

  1. Categorical variables are expressed in percentage (absolute count). Continuous variables are expressed in median (percentile 25; percentile 75). P-values were estimated with nonparametric Mann–Whitney U test for continuous variable and Chi-square test for categorical variable.
  2. Abbreviations: AIDS acquired immunodeficiency syndrome, BMI body mass index, cART combination antiretroviral therapy, HCV hepatitis C virus, HCV-RNA HCV plasma viral load, HIV human immunodeficiency virus, HIV-RNA HIV plasma viral load, IVDU intravenous drug users, NNRTI no nucleoside analog reverse-transcriptase inhibitors, NRTI nucleoside analog reverse-transcriptase inhibitors, PI protease inhibitors.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us